Clinical Trials Logo

Allergic Rhinoconjunctivitis clinical trials

View clinical trials related to Allergic Rhinoconjunctivitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05668390 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma

YOBI
Start date: November 14, 2023
Phase: Phase 3
Study type: Interventional

Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and watery eyes). For several birch-allergic patients, allergic rhinoconjunctivitis occurs with an oral allergy syndrome. The purpose of this study is to demonstrate the safety and efficacy of the study drug (STALORAL Birch 300 IR) in children and adolescents with birch pollen-induced allergic rhinoconjunctivitis, with or without asthma, when treated before and during the pollen season. Approximately 699 children will participate in this study. The study will be conducted worldwide in approximately 100 medical sites in about 14 countries. The total duration of the study will be approximately 20 months.

NCT ID: NCT04502966 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

GRADUATE
Start date: November 9, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess whether the combination of grass allergen sublingual immunotherapy (SLIT) and dupilumab for 2 years is more effective than double placebo in suppressing the nasal allergen challenge (NAC) response to grass pollen at 1 year after completion of study medication.

NCT ID: NCT00812799 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.